Sonrotocrax と BRUKINSA は、危険性の高い患者を含め,無菌CLL患者の完全な完結に近づいた。 Sonrotoclax with BRUKINSA achieved near-complete remission in untreated CLL patients, including high-risk cases, in a 2025 study.

2025年のASH年次会議で,BeOne Medicinesは,BRUKINSAと併用したsonrotoclaxが,高リスクの遺伝特性を有する患者を含む,治療前のCLL患者で,迅速かつ持続的な検出不能の最小残留疾患 (uMRD) を達成したと報告した. At the 2025 ASH Annual Meeting, BeOne Medicines reported that sonrotoclax combined with BRUKINSA achieved rapid and sustained undetectable minimal residual disease (uMRD) in treatment-naive CLL patients, including those with high-risk genetic features. 98%の患者が 96週までに UID4に達し わずか1週間の 平均時間と 100%の反応率です In a Phase 1/2 study, 98% of patients reached uMRD4 by 96 weeks, with a median time to uMRD4 of just weeks, and a 100% overall response rate. R/R/MCLでは,ソロトクラックス独占療法では,危険性の高いサブグループにおける全反応率と耐久反応の52%が確認され,米国の加速的な承認をサポートした. In R/R MCL, sonrotoclax monotherapy showed a 52.4% overall response rate and durable responses in high-risk subgroups, supporting potential U.S. accelerated approval. このデータは,B細胞悪性腫瘍におけるソントロクラクスの有望性を強調しています. The data highlight sonrotoclax’s promise across B-cell malignancies.